Vaccination with OK-432 followed by TC-1 tumor lysate leads to significant antitumor effects

Reproductive Sciences

Volumn 18, Issue 7, 2011, Pages 687-694

  Chen, I Ju ^a   Yen, Chih Feng ^a   Lin, Kun Ju ^a   Lee, Chyi Long ^a   Soong, Yung Kuei ^a   Lai, Chyong Huey ^a   Lin, Cheng Tao ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

dendritic cell; OK 432; TC 1 cells; tumor lysate; vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; PICIBANIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LYSATE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HELPER CELL; IMMUNE RESPONSE; IN VIVO STUDY; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TC 1 TUMOR LYSATE; TUMOR IMMUNITY;

ALPHAPAPILLOMAVIRUS; ANIMALS; CELL LINE, TUMOR; FEMALE; MICE; MICE, INBRED C57BL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PICIBANIL; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 79959520958     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719110396230     Document Type: Article

References (34)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 ; 189 (1). 12-19 (Pubitemid 29406813)
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005 ; 55 (2). 74-108 (Pubitemid 40372904)
3. Itoh T, Ueda Y, Okugawa K, et al. Streptococcal preparation OK432 promotes functional maturation of human monocyte-derived dendritic cells. Cancer Immunol Immunother. 2003 ; 52 (4). 207-214 (Pubitemid 36535280)
4. Ono T, Kurata S, Wakabayashi K, Sugawara Y, Saito M. Inhibitory effect of a streptococcal preparation (OK-432) on the nucleic acid synthesis in tumor cells in vitro. Gann Gan. 1973 ; 64 (1). 59-64
5. Oshimi K, Kano S, Takaku F, Okumura K. Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432. J Nation Cancer Ins. 1980 ; 65 (6). 1265-1269 (Pubitemid 11196015)
6. Saito M, Nanjo M, Kataoka M, et al. Adoptive immunotherapy by pantropic killer cells recovered from OK-432-injected tumor sites in mice. Cancer Res. 1988 ; 48 (15). 4163-4167
7. Saito M, Nanjo M, Aonuma E, et al. Activated macrophages are responsible for the tumor-inhibitory effect in mice receiving intravenous injection of OK-432. Int J Cancer. 1984 ; 33 (2). 271-276 (Pubitemid 14184418)
8. Shitara K, Ichimura O, Mitsuno T, Osawa T. Natural killer (NK) cell activating factor released from murine thymocytes stimulated with an anti-tumor streptococcal preparation, OK-432. J Immunol. 1985 ; 134 (2). 1039-1047 (Pubitemid 15157298)
9. Wakasugi H, Kasahara T, Minato N, Hamuro J, Miyata M, Morioka Y. In vitro potentiation of human natural killer cell activity by a streptococcal preparation, OK-432: interferon and interleukin-2 participation in the stimulation with OK-432. J Nation Cancer Ins. 1982 ; 69 (4). 807-812 (Pubitemid 12001194)
10. Kitsuki H, Katano M, Ikubo A, et al. Induction of inflammatory cytokines in effusion cavity by OK-432 injection therapy for patients with malignant effusion: role of interferon-gamma in enhancement of surface expression of ICAM-1 on tumor cells in vivo. Clinical Immunol Immunopathol. 1996 ; 78 (3). 283-290 (Pubitemid 26127990)
11. Okamoto T, Harada M, Tamada K, et al. Local injection of OK432 can augment the TH1-type T-cell response in tumor-draining lymph node cells and increase their immunotherapeutical potential. Int J Cancer. 1997 ; 70 (5). 598-605 (Pubitemid 27149647)
12. Ryoma Y, Moriya Y, Okamoto M, Kanaya I, Saito M, Sato M. Biological effect of OK-432 (picibanil) and possible application to dendritic cell therapy. Anticancer Res. 2004 ; 24 (5C). 3295-3301 (Pubitemid 39390944)
13. Mittendorf EA, Holmes JP, Ponniah S, Peoples GE. The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother. 2008 ; 57 (10). 1511-1521
14. Lin CT, Tsai YC, He L, et al. DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity. Immunol Lett. 2007 ; 114 (2). 86-93 (Pubitemid 350180096)
15. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nature Rev. 2002 ; 2 (5). 342-350 (Pubitemid 37328947)
16. Lin CT, Hung CF, Juang J, et al. Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles. Mol Ther. 2003 ; 8 (4). 559-566 (Pubitemid 37321684)
17. Wu A, Zeng Q, Kang TH, et al. Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer. Gene Ther. 2010 ;:
18. Lin CT, Yen TC, Chang TC, et al. Role of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in re-recurrent cervical cancer. Int J Gynecol Cancer. 2006 ; 16 (6). 1994-2003
19. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 1998 ; 4 (3). 321-327 (Pubitemid 28144091)
20. Hohn H, Pilch H, Gunzel S, et al. CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7. J Immunol. 1999 ; 163 (10). 5715-5722
21. Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine MD. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS (London, England). 1998 ; 12 (12). 1459-1464 (Pubitemid 28369645)
22. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003 ; 421 (6925). 852-856 (Pubitemid 36254145)
23. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science (New York, NY.). 2003 ; 300 (5617). 337-339 (Pubitemid 36433726)
24. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science (New York, NY). 2003 ; 300 (5617). 339-342 (Pubitemid 36433727)
25. van de Berg PJ, van Leeuwen EM, ten Berge IJ, van Lier R. Cytotoxic human CD4(+) T cells. Curr Opin Immunol. 2008 ; 20 (3). 339-343
26. Okamoto M, Oh EG, Oshikawa T, et al. Toll-like receptor 4 mediates the antitumor host response induced by a 55-kilodalton protein isolated from Aeginetia indica L., a parasitic plant. Clin Diagnos lab Immunol. 2004 ; 11 (3). 483-495 (Pubitemid 38661414)
27. Koido S, Hara E, Homma S, et al. Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells. J Immunol. 2007 ; 178 (1). 613-622 (Pubitemid 46033645)
28. Mashino K, Sadanaga N, Tanaka F, Ohta M, Yamaguchi H, Mori M. Effective strategy of dendritic cell-based immunotherapy for advanced tumor-bearing hosts: the critical role of Th1-dominant immunity. Mol Cancer Therap. 2002 ; 1 (10). 785-794
29. Schultz ES, Chapiro J, Lurquin C, et al. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J Exp Med. 2002 ; 195 (4). 391-399 (Pubitemid 34461293)
30. Robinson DS, O'Garra A. Further checkpoints in Th1 development. Immunity. 2002 ; 16 (6). 755-758 (Pubitemid 34786474)
31. Kurosawa S, Harada M, Shinomiya Y, Terao H, Nomoto K. The concurrent administration of OK432 augments the antitumor vaccination effect with tumor cells by sustaining locally infiltrating natural killer cells. Cancer Immunol Immunother. 1996 ; 43 (1). 31-38 (Pubitemid 26360156)
32. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, et al. NK cells and cancer. J Immunol. 2007 ; 178 (7). 4011-4016 (Pubitemid 46492347)
33. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989 ; 170 (3). 827-845 (Pubitemid 19226667)
34. Okamoto M, Kaji R, Kasetani H, et al. Purification and characterization of interferon-gamma-inducing molecule of OK-432, a penicillin-killed streptococcal preparation, by monoclonal antibody neutralizing interferon-gamma-inducing activity of OK-432. J Immunother Emphasis Tumor Immunol. 1993 ; 13 (4). 232-242 (Pubitemid 23163688)